Gonadorelin Acetate

Overview

Gonadorelin Acetate is the synthetic acetate salt form of native hypothalamic gonadotropin-releasing hormone (GnRH/LHRH), a linear decapeptide (10 amino acids) with C-terminal amidation. Vialdyne releases Gonadorelin Acetate as a lyophilized peptide against a ≥99.0% HPLC main-peak specification, supplied with a batch-specific Certificate of Analysis covering RP-HPLC purity, mass-spec identity and appearance; water content is available on request and listed on the COA when tested. Lots are released only after the COA is on file.

Applications & buyer fit

GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want loose-format lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS

33515-09-2

Molecular Formula

C55H75N17O13

Molecular Weight

1182.3 g/mol (free base)

Sequence

pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

2 mg – 5 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 2-10 minutes

MOQ

On request

Lead time

10–18 days

Storage

-20°C lyophilized; 2–8°C reconstituted, protect from light

Certificate of Analysis

Representative COA previews for Gonadorelin Acetate; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

Gonadorelin Acetate

VD260428-GNRH088 · 99.12%

VerifiedRequest full COA →

Gonadorelin Acetate

VD260428-GNRH089 · 99.57%

Regulatory note

Research-use-only reference material; not for human or veterinary use.

Selected literature

1. Hoffman AR, Crowley WF Jr. Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone. N Engl J Med. 1982;307(20):1237-1241.
2. Happ J, Ditscheid W, Krause U. Pulsatile gonadotropin-releasing hormone therapy in male patients with Kallmann's syndrome or constitutional delay of puberty. Fertil Steril. 1985;43(4):599-608.
3. Filicori M. Pulsatile gonadotropin-releasing hormone: clinical applications of a physiologic paradigm. F S Rep. 2023;4(2 Suppl):20-26.
4. Paulson RJ, Gordon K. Gonadotropin-releasing hormone: incredible 50 years. F S Rep. 2023;4(2 Suppl):1-2.
5. Akın O, Yavuz ST, Hacıhamdioğlu B, Sarı E, Gürsel O, Yeşilkaya E. Anaphylaxis to gonadorelin acetate in a girl with central precocious puberty. J Pediatr Endocrinol Metab. 2015;28(11-12):1387-1389.
6. Ab Rahim SN, Omar J, Tuan Ismail TS. Gonadotropin-releasing hormone stimulation test and diagnostic cutoff in precocious puberty: a mini review. Ann Pediatr Endocrinol Metab. 2020;25(3):152-155.

Frequently asked questions